Literature DB >> 17624505

[Lymphologic liposculpture].

M E Cornely1.   

Abstract

Surgical approaches are usually not part of the strand rad approach in lymphologic therapy. Classic therapy is conservative and controls symptoms rather than seeking cures. Plastic surgical tissue reduction results in impaired lymph flow in many cases. Improving the lymphologic disease while reducing the need for complex compression therapy are major therapeutic goals. Lymphologic liposculpture offers a successful way to treat lipohyperplasia dolorosa and offers a new concept in the treatment of secondary lymphedema.

Entities:  

Mesh:

Year:  2007        PMID: 17624505     DOI: 10.1007/s00105-007-1367-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  3 in total

1.  Microlymphatic aneurysms in patients with lipedema.

Authors:  B R Amann-Vesti; U K Franzeck; A Bollinger
Journal:  Lymphology       Date:  2001-12       Impact factor: 1.286

Review 2.  Liposuction gives complete reduction of chronic large arm lymphedema after breast cancer.

Authors:  H Brorson
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

3.  Liposuction reduces arm lymphedema without significantly altering the already impaired lymph transport.

Authors:  H Brorson; H Svensson; K Norrgren; O Thorsson
Journal:  Lymphology       Date:  1998-12       Impact factor: 1.286

  3 in total
  3 in total

Review 1.  [Fatter through lipids or water. Lipohyperplasia dolorosa versus lymphedema].

Authors:  M E Cornely
Journal:  Hautarzt       Date:  2010-10       Impact factor: 0.751

2.  The Addition of Hyaluronidase to Tumescent Local Anesthesia Supports Lymphological Liposculpture of Secondary Lymphedema.

Authors:  Manuel Eugen Cornely; Christian Hettenhausen
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-12-10

3.  A randomised controlled multicentre investigator-blinded clinical trial comparing efficacy and safety of surgery versus complex physical decongestive therapy for lipedema (LIPLEG).

Authors:  Maurizio Podda; Maximilian Kovacs; Martin Hellmich; Rebecca Roth; Marouan Zarrouk; Daria Kraus; Reinhild Prinz-Langenohl; Oliver A Cornely
Journal:  Trials       Date:  2021-10-30       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.